STAT Plus Latest

Pharmalot

Drug and device makers paid teaching hospitals $832 million in 2018, creating potential for conflicts of interest

By Ed Silverman

Health Tech

Dan Trigub, head of Uber Health, is leaving to launch a health care startup

By Erin Brodwin

Pharmalot

Pharmalittle: Covid-19 vaccine makers pledge to prioritize safety and efficacy; is Operation Warp Speed working?

By Ed Silverman

Pharma

Merck chronic cough drug shows mixed results in late-stage clinical trials, raising questions about its future

By Adam Feuerstein

Pharmalot

‘An unchartered situation for all of us’: From shipping containers to security concerns, a Covid-19 vaccine supply chain takes shape

By Ed Silverman

Biotech

Plasma giant Grifols to buy Silicon Valley startup targeting blood proteins for age-related diseases

By Rebecca Robbins

Biotech

Blueprint Medicines wins U.S. approval for genetically targeted lung cancer drug

By Adam Feuerstein

Pharmalot

A second U.S. agency will review if Moderna disclosed federal funding in vaccine patents

By Ed Silverman

Biotech

‘The race is on’: China’s I-Mab gets boost from AbbVie to develop a new cancer immunotherapy

By Jonathan Chan

Pharmalot

Pharmalittle: Slaoui vows to quit OWS if politics trumps vaccine science; do we have enough freezers?

By Elizabeth Cooney

Pharmalot

Up and down the ladder: The latest comings and goings

By Ed Silverman

Something Ventured

Oncorus and three other startups got venture funding a year ago. Did it help them do what they said it would?

By Kate Sheridan

Health Tech

Biofourmis raises $100 million for remote patient monitoring tools

By Andy Rosen — Boston Globe

Biotech

Amarin loses appeal over heart drug patent, dashing its commercial hopes

By Damian Garde

Pharmalot

Pharmalittle: States asked to speed Covid-19 vaccine distribution sites; NIH panel contradicts FDA on plasma

By Ed Silverman

Politics

How Trump could use a rare regulatory maneuver to lower drug prices before Election Day, and how it could backfire

By Nicholas Florko

Pharmalot

Pharmalittle: U.S. won’t join WHO Covid-19 vaccine program; experts say a vaccine is possible this fall

By Ed Silverman

Health

You had questions about precision medicine. Stanford’s Lloyd Minor has answers

By STAT staff

Health Tech

What we learned about the business of telemedicine from Amwell and GoodRx’s IPO filings

By Rebecca Robbins

Pharmalot

FDA cites Mylan for ‘repeated failures’ at manufacturing plants in India

By Ed Silverman

Health Tech

STAT+ Conversations: How the Chan Zuckerberg Initiative is prioritizing its funding for the Covid-19 response

By Rebecca Robbins

Pharmalot

Congressional committee to subpoena AbbVie in drug pricing investigation

By Ed Silverman

In the Lab

In research on middle-aged mice, scientists find a metabolite that leads to a longer, healthier life

By Pratibha Gopalakrishna

Pharmalot

Pharmalittle: Sanofi drug fails to tackle serious Covid-19 cases; EC agrees to fund WHO Covax program

By Ed Silverman

Politics

Small vape makers seek another extension on a looming FDA application deadline, sparking battle with advocates

By Nicholas Florko

The Pony Express? U.S. Postal Service changes continue to slow down deliveries of mail-order prescriptions

Liquid biopsy startup Grail, in filing for IPO, lays out investments and plans for growth

Pharmalittle: AstraZeneca pauses its Covid-19 vaccine trial; FDA sticking with its vaccine approval guidelines

Can AI improve cancer diagnosis in real patients? The U.S. military has enlisted Google to find out

Drug and device makers paid teaching hospitals $832 million in 2018, creating potential for conflicts of interest

Dan Trigub, head of Uber Health, is leaving to launch a health care startup

Pharmalittle: Covid-19 vaccine makers pledge to prioritize safety and efficacy; is Operation Warp Speed working?

Merck chronic cough drug shows mixed results in late-stage clinical trials, raising questions about its future

‘An unchartered situation for all of us’: From shipping containers to security concerns, a Covid-19 vaccine supply chain takes shape

Plasma giant Grifols to buy Silicon Valley startup targeting blood proteins for age-related diseases

Blueprint Medicines wins U.S. approval for genetically targeted lung cancer drug

A second U.S. agency will review if Moderna disclosed federal funding in vaccine patents

‘The race is on’: China’s I-Mab gets boost from AbbVie to develop a new cancer immunotherapy

Pharmalittle: Slaoui vows to quit OWS if politics trumps vaccine science; do we have enough freezers?

Up and down the ladder: The latest comings and goings

Oncorus and three other startups got venture funding a year ago. Did it help them do what they said it would?

Biofourmis raises $100 million for remote patient monitoring tools

Amarin loses appeal over heart drug patent, dashing its commercial hopes

Pharmalittle: States asked to speed Covid-19 vaccine distribution sites; NIH panel contradicts FDA on plasma

How Trump could use a rare regulatory maneuver to lower drug prices before Election Day, and how it could backfire

Pharmalittle: U.S. won’t join WHO Covid-19 vaccine program; experts say a vaccine is possible this fall

You had questions about precision medicine. Stanford’s Lloyd Minor has answers

What we learned about the business of telemedicine from Amwell and GoodRx’s IPO filings

FDA cites Mylan for ‘repeated failures’ at manufacturing plants in India

STAT+ Conversations: How the Chan Zuckerberg Initiative is prioritizing its funding for the Covid-19 response

Congressional committee to subpoena AbbVie in drug pricing investigation

In research on middle-aged mice, scientists find a metabolite that leads to a longer, healthier life

Pharmalittle: Sanofi drug fails to tackle serious Covid-19 cases; EC agrees to fund WHO Covax program

Small vape makers seek another extension on a looming FDA application deadline, sparking battle with advocates